These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 38338453)

  • 1. Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction.
    Thilakarathna WPDW; Rupasinghe HPV
    Molecules; 2024 Feb; 29(3):. PubMed ID: 38338453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
    Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.
    Sharpton SR; Maraj B; Harding-Theobald E; Vittinghoff E; Terrault NA
    Am J Clin Nutr; 2019 Jul; 110(1):139-149. PubMed ID: 31124558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.
    Liu L; Li P; Liu Y; Zhang Y
    Dig Dis Sci; 2019 Dec; 64(12):3402-3412. PubMed ID: 31203554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.
    Khan MY; Mihali AB; Rawala MS; Aslam A; Siddiqui WJ
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):703-715. PubMed ID: 31009401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD.
    Perumpail BJ; Li AA; John N; Sallam S; Shah ND; Kwong W; Cholankeril G; Kim D; Ahmed A
    Diseases; 2019 Feb; 7(1):. PubMed ID: 30823570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.
    Mahapatro A; Bawna F; Kumar V; Daryagasht AA; Gupta S; Raghuma N; Moghdam SS; Kolla A; Mahapatra SS; Sattari N; Amini-Salehi E; Nayak SS
    Clin Nutr ESPEN; 2023 Oct; 57():475-486. PubMed ID: 37739694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.
    Kaufmann B; Seyfried N; Hartmann D; Hartmann P
    Am J Physiol Gastrointest Liver Physiol; 2023 Jul; 325(1):G42-G61. PubMed ID: 37129252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients.
    Buss C; Valle-Tovo C; Miozzo S; Alves de Mattos A
    Ann Hepatol; 2014; 13(5):482-8. PubMed ID: 25152979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Rong L; Ch'ng D; Jia P; Tsoi KKF; Wong SH; Sung JJY
    J Gastroenterol Hepatol; 2023 Oct; 38(10):1682-1694. PubMed ID: 37409560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity of polymeric proanthocyanidins is caused by translocation of bacterial lipopolysaccharides through impaired gut epithelium.
    Thilakarathna WPDW; Langille MGI; Rupasinghe HPV
    Toxicol Lett; 2023 Apr; 379():35-47. PubMed ID: 36935082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.